News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

All Stories

All
News
Press Releases
News

Scribe Therapeutics plans to test cholesterol-lowering epigenetic editing therapy

January 14, 2026

Endpoints

Read Now
News

CRISPR Slashes ‘Bad Cholesterol’ Levels by 95 Percent in Early Results

November 27, 2025

Singularity Hub

Read Now
News

Can AI take the guesswork out of CRISPR?

November 24, 2025

Drug Discovery News

Read Now
News

Can genetic medicine solve cardiovascular disease?

November 20, 2025

Longevity.Technology

Read Now
News

Scribe eyes clinic after CRISPR candidates lower lipids in animals

November 17, 2025

Fierce Biotech

Read Now
News

Epigenetic approach shows durable PCSK9 silencing in primates

October 15, 2025

BioWorld

Read Now
Press release

Scribe Therapeutics Reports Positive Preclinical Data on its Novel CRISPR Technologies at the 2025 EAS Congress and ASGCT Annual Meeting

May 22, 2025

Read Now
Press release

Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular Dystrophy at ASGCT 2025, in Addition to Joint Presentation with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division

May 5, 2025

Read Now
Press release

Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders

April 28, 2025

Read Now
Press release

Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress

April 23, 2025

Read Now
Press release

Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference

March 7, 2025

Read Now
Press release

Scribe Therapeutics to Participate in Upcoming Conferences

February 26, 2025

Read Now

Publications and presentations